Clinical Trials Logo

Filter by:
NCT ID: NCT06232304 Not yet recruiting - Clinical trials for Systemic Lupus Erythematosus of Childhood (Disorder)

Transforming Care for Individuals With Childhood-onset Systemic Lupus Erythematosus

cSLE
Start date: April 1, 2024
Phase: N/A
Study type: Interventional

This study aims to investigate the feasibility and effectiveness of a cognitive behavioral coping skills program, Treatment and Education Approach for Childhood-onset Lupus (TEACH), for youth with cSLE when integrated into medical care. This TEACH program aims to teach participants skills in order to cope with fatigue, pain, and depressive symptoms--symptoms that commonly affect adolescents and young adults with lupus.

NCT ID: NCT06232941 Not yet recruiting - Vital Pulp Therapy Clinical Trials

Comparative Evaluation of Three Pulpotomy Agents for Permanent Mature Molars With Irreversible Pulpitis

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

Statement of the problem: Accurate pulpal diagnosis is essential for decision making between vital pulp therapy and root canal treatment. Clinical and radiographic examinations do not correctly reflect the histological state of the pulp and consequently its ability to heal. Also, despite the various advantages of using MTA as a pulp capping agent, it has several drawbacks. Aim of the study: The aim of the study is to compare two types of calcium silicate-based materials to MTA in permanent mature molars diagnosed with irreversible pulpitis regarding the following parameters; level of inflammatory biomarker level, clinical and radiographic outcomes. Materials and methods: Thirty-six patients with mature permanent molars exhibiting signs and symptoms indicative of irreversible pulpitis will be enrolled. A careful periodontal treatment and standardized operative procedure will be followed for all participants. Gingival crevicular fluid samples will be obtained before any local anesthetics' administration, followed by isolation of teeth with a dental dam and removal of caries. Pulpotomy will be performed using sterile round bur till level of orifices and then haemostasis will be achieved using sodium hypochlorite. At this point, patients will be randomly divided into three groups of 12 depending on the type of calcium silicate-based material used. Later, resin modified glass ionomer will be applied, etching, bonding and placement of composite as the permanent restoration. Follow up clinically and radiographically will be done.

NCT ID: NCT06234150 Not yet recruiting - Breast Neoplasms Clinical Trials

Aerobic Dance During Chemotherapy in Breast Cancer Patients With Cognitive Impairment

ADANC
Start date: April 1, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to learn about breast cancer patients. The main questions it aims to answer are: - Does Aerobic Dance During Chemotherapy Improve Cognitive Function in Breast Cancer Patients? - Does the efficacy of aerobic dance differ from fast walking of equal intensity? Recruited patients will be randomly assigned to three groups: (1) aerobic dance group, (2) fast walking group, and (3) usual care group. The aerobic dance and fast-walking groups participated in supervised exercise lasting 50 minutes thrice a week for 12 weeks. The goal of this study's findings is to develop practical strategies for managing breast cancer-related cognitive impairment.

NCT ID: NCT06237725 Not yet recruiting - Enteral Nutrition Clinical Trials

Abdominal Massage in Enteral Nutrition Patients

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

Complications related to the gastrointestinal system may arise in patients receiving enteral nutrition through continuous and bolus infusion. These complications include constipation, diarrhea, nausea, vomiting, abdominal distension, increased gastric residual volume, and abdominal pain. The aim of this study is to determine the impact of abdominal massage applied to patients receiving enteral nutrition through continuous or bolus infusion on gastrointestinal system functions. For this purpose, 164 patients meeting the inclusion criteria will be randomized, and four groups will be defined. Half will constitute the experimental group, and the others will form the control group. In our study, the effects of massage on symptom control will be evaluated by comparing symptoms in patients receiving both forms of nutrition. Thus, the evaluation and control of medical conditions (symptoms) such as constipation, diarrhea, vomiting, increased abdominal distension, and increased gastric residual volume are targeted.

NCT ID: NCT06238167 Not yet recruiting - Gastric Cancer Clinical Trials

Tislelizumab Plus Chemotherapy as Postoperative Adjuvant Therapy in Elderly Patients With LA GC/GEJC

Start date: April 1, 2024
Phase: Phase 2
Study type: Interventional

The purpose of study is to evaluate the efficacy and safety of postoperative adjuvant chemotherapy with tislelizumab in combination with tegafur-gimeracil-oteracil potassium (S-1 therapy) or tegafur-gimeracil-oteracil potassium + oxaliplatin (SOX therapy) in PD-L1 CPS positive, elderly (≥70years old), pStage III gastric cancer (including esophagogastric junction cancer) after D2 dissection.

NCT ID: NCT06239025 Not yet recruiting - Postoperative Pain Clinical Trials

Efficacy of Transversus Thoracis Muscle Plane Block in Patients Undergoing Cardiac Surgery

TTMP_Block
Start date: April 1, 2024
Phase: Phase 4
Study type: Interventional

The goal of this randomized double blind study is to evaluate the analgesic efficacy of Transversus Thoracis Muscle Plane Block in patients undergoing cardiac surgery with median sternotomy. one group of participants will receive multimodal analgesia plus ultrasound-guided Transversus Thoracis Muscle Plane Block with ropivacaine 0.5 % after induction of general anesthesia, the other group will receive multimodal analgesia without a bloc. The investigators want to know if participants who receive the Transversus Thoracis Muscle Plane Block with ropivacaine have less pain than participants who do not receive a block.

NCT ID: NCT06239571 Not yet recruiting - Parents Clinical Trials

Resilient Families

R-FAM
Start date: April 1, 2024
Phase: Phase 1
Study type: Interventional

The goal is to develop, refine, and test the feasibility and acceptability of a dyadic, resiliency intervention ("Resilient Families;" R-FAM) that aims to reduce emotional distress and improve relationships among parents in the Neonatal Intensive Care Unit (NICU). To achieve this goal, my aims are three-fold: (1) develop R-FAM using stakeholder input from interviews with parent dyads and focus groups with NICU staff; (2) optimize R-FAM through an open pilot with pre/post assessments and exit interviews; and (3) test R-FAM for feasibility and acceptability through a randomized clinical trial of R-FAM compared with a minimally enhanced usual control (MEUC).

NCT ID: NCT06239675 Not yet recruiting - Clinical trials for Cerebral Palsy, Hemiplegic

Cerebral pAlsy Motor Promotion With Transcranial Direct Current Stimulation (CAMP-tDCS)

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

This study aims to test if transcranial direct current stimulation (tDCS) can be applied to boost the efficacy of constraint-induced movement therapy (CIMT) in children with HCP and examine brain mechanisms related to individual outcomes.

NCT ID: NCT06240780 Not yet recruiting - Clinical trials for Anterior Cruciate Ligament Reconstruction

Incrediwear ACL MCL Arthroscopic Surgery Recovery Study

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to assess the benefits of using the Incrediwear knee products after anterior cruciate ligament arthroscopic surgery or anterior cruciate ligament and medial collateral ligament (ACL+MCL) arthroscopic surgery, on the postoperative pain, range of motion and effusion. Participant population includes female or male patients in relative good health, 18 to 65 years old. The investigators will compare participants with Incrediwear and placebo Incrediwear products during the first 6-month postoperative period. The main question it aims to answer are: - Will the Incrediwear products help participants to decrease postoperative pain and swelling? - Will the Incrediwear products help the participants by increasing the range of motion in a shorter amount of time than the placebo group? Participants will be asked to maintain a journal documenting surgical site pain, pain medication type and quantity taken. Researcher will compare 90 participants enrolled in one of six groups, double blinded and randomly assigned, to see if the Incrediwear products assist in controlling postoperative swelling, and increase range of motion in a shorter amount of time. - ACL participants randomly assigned the Incrediwear product, placebo product, or none - ACL+MCL participants randomly assigned the Incrediwear product, placebo product, or none

NCT ID: NCT06242522 Not yet recruiting - Clinical trials for Immune Checkpoint Inhibitors

Fertility and Pregnancy After Avelumab Treatment

FERTILAVE
Start date: April 1, 2024
Phase: N/A
Study type: Interventional

Immune checkpoint inhibitors (ICIs), such as anti-PD-1/PD-L1 agents, initially evaluated in advanced non-curative pathologies, are now being evaluated in adjuvant or even neoadjuvant curative treatment conditions. This paradigm shift is leading to the treatment of young women, particularly in the context of gestational trophoblastic tumours. Given the potential autoimmune side-effects affecting endocrine functions, as well as their impact on maternal-foetal tolerance mechanisms, accurate assessment of post-ICT fertility is necessary. In the coming years, treatment with anti-PD-L1 (avelumab) could become a cornerstone of the therapeutic strategy for patients with gestational trophoblastic tumours. However, these patients are often young and of childbearing age, so safety of use in terms of fertility and successful pregnancies is an essential factor in the widespread use of immunotherapy as a treatment option. Some studies have reported the possibility of conceiving after avelumab treatment, but no cohort has been reported. This study aims to explore fertility and the course of potential pregnancy in 50 patients treated with anti-PD-L1 (avelumab) over the last 5 years in several French centres.